Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
GLOW 70mg
70mg
Related Research News
Rugiet Launches Peptide and Longevity Therapies: Ozempic News Context
Rugiet has launched a new line of physician-prescribed peptide and longevity therapies, setting a standard for performance medicine. This development comes amid ongoing ozempic news and interest in weight management drugs like Wegovy. The article explores the implications for peptide researchers and industry professionals.
GLP-1 Agonists Linked to Better Breast Cancer Survival Signals
A large retrospective study in JAMA Network Open links GLP-1 receptor agonist use to improved survival and recurrence outcomes in women with breast cancer, obesity, or type 2 diabetes. The analysis from 841,831 patients shows strong hazard ratios, such as 0.35 for mortality in obesity cases. Observational data raises questions about causality and confounding.